Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Sep;28(9):825-33.
doi: 10.1007/s40263-014-0181-3.

Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder

J A Santisteban  1 , M A Stein, L Bergmame, R Gruber
Affiliations
Randomized Controlled Trial

Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder

J A Santisteban et al. CNS Drugs. 2014 Sep.

Abstract

Objective: We sought to determine the dose-response effects of extended-release (ER) dexmethylphenidate (d-MPH) and ER mixed amphetamine salts (MAS) on objective measures of sleep.

Methods: This was an 8-week, double-blind, placebo-controlled, randomized, two period, crossover study of youth with attention-deficit hyperactivity disorder (ADHD) as confirmed by the Kiddie Schedule for Affective Disorders for School-Age Children-Present and Lifetime version (K-SADS-PL). Children aged 10-17 years were recruited from clinical practice, colleague referrals, and flyers. Participants were randomized to initially receive either d-MPH or MAS. During each 4-week drug period, children received three dose levels (10, 20, and 25/30 mg) in ascending order, with placebo substituted for active medication in a randomized fashion during 1 week of the study. After 4 weeks, participants were switched to the alternative medication for another 4 weeks of treatment. The main outcome measure was sleep duration as measured by actigraphy. Children, parents, and researchers were blinded to drug, dose, and placebo status.

Results: Sixty-five participants met the inclusion criteria and were enrolled in the study. Of these, 37 participants with sufficient sleep data for analysis were included. Sleep schedule measures showed a significant effect for dose on sleep start time (F(1,36) = 6.284; p < 0.05), with a significantly later sleep start time when children were receiving 20- or 30-mg doses, compared with placebo (p < 0.05). A significant dose effect was found on actual sleep duration (F(1,36) = 8.112; p < 0.05), with significantly shorter actual sleep duration for subjects receiving 30 mg compared with those receiving placebo (p < 0.05). There were no significant differences on sleep duration or sleep schedule between the two stimulant medications. The trial is complete and closed to follow-up.

Conclusions: Higher stimulant doses were associated with reduced sleep duration and later sleep start times, regardless of medication class.

Trial registration: ClinicalTrials.gov: NCT00393042.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Example of a treatment schedule. Each treatment modality lasts for 1 week, for a total of 8 weeks. MAS mixed amphetamine salts, d-MPH dexmethylphenidate
Fig. 2
Fig. 2
Sleep duration for MAS and d-MPH at all doses. Mean sleep duration decreases with higher doses for both medications. There are significant differences in mean duration during both placebo (asterisk) and 10-mg treatment (double asterisk) compared with 20 and 30 mg treatment (p<0.05). MAS mixed amphetamine salts, d-MPH dexmethylphenidate
Fig. 3
Fig. 3
Sleep schedule: sleep start time for MAS and d-MPH at all doses. Mean sleep start time occurs later with higher doses for both medications. There are significant differences in mean sleep start time during placebo compared with 20- and 30-mg treatment (p<0.05) [asterisk]. There was also a significant difference between 10-mg treatment and 30-mg treatment (p<0.05) [double asterisk]. MAS mixed amphetamine salts, d-MPH dexmethylphenidate
See this image and copyright information in PMC

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th American Psychiatric Association; Washington, DC: 2013.
    1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. doi:10.1176/appi.ajp.164.6.942. - PubMed
    1. Volkow ND, Tomasi D, Wang G-J, Telang F, Fowler JS, Logan J, et al. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci. 2012;32(19):6711–7. doi:10.1523/jneurosci.0045-12.2012. - PMC - PubMed
    1. Arnsten AT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology. CNS Drugs. 2009;23(1):33–41. doi:10.2165/00023210-200923000-00005. - PubMed
    1. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98(6):1084–8. - PubMed

Publication types

MeSH terms

Associated data